These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20356739)

  • 1. Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.
    Nolan KA; Humphries MP; Bryce RA; Stratford IJ
    Bioorg Med Chem Lett; 2010 May; 20(9):2832-6. PubMed ID: 20356739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.
    Dunstan MS; Barnes J; Humphries M; Whitehead RC; Bryce RA; Leys D; Stratford IJ; Nolan KA
    J Med Chem; 2011 Oct; 54(19):6597-611. PubMed ID: 21859103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
    Nolan KA; Caraher MC; Humphries MP; Bettley HA; Bryce RA; Stratford IJ
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7331-6. PubMed ID: 21074425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.
    Nolan KA; Humphries MP; Barnes J; Doncaster JR; Caraher MC; Tirelli N; Bryce RA; Whitehead RC; Stratford IJ
    Bioorg Med Chem; 2010 Jan; 18(2):696-706. PubMed ID: 20036559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of analogues of furan-amidines as inhibitors of NQO2.
    Alnabulsi S; Hussein B; Santina E; Alsalahat I; Kadirvel M; Magwaza RN; Bryce RA; Schwalbe CH; Baldwin AG; Russo I; Stratford IJ; Freeman S
    Bioorg Med Chem Lett; 2018 May; 28(8):1292-1297. PubMed ID: 29567345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.
    Dufour M; Yan C; Siegel D; Colucci MA; Jenner M; Oldham NJ; Gomez J; Reigan P; Li Y; De Matteis CI; Ross D; Moody CJ
    Chembiochem; 2011 May; 12(8):1203-8. PubMed ID: 21506232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).
    Hussein B; Ikhmais B; Kadirvel M; Magwaza RN; Halbert G; Bryce RA; Stratford IJ; Freeman S
    Eur J Med Chem; 2019 Nov; 182():111649. PubMed ID: 31514018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
    den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
    Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico screening reveals structurally diverse, nanomolar inhibitors of NQO2 that are functionally active in cells and can modulate NF-κB signaling.
    Nolan KA; Dunstan MS; Caraher MC; Scott KA; Leys D; Stratford IJ
    Mol Cancer Ther; 2012 Jan; 11(1):194-203. PubMed ID: 22090421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.
    Yan C; Dufour M; Siegel D; Reigan P; Gomez J; Shieh B; Moody CJ; Ross D
    Biochemistry; 2011 Aug; 50(31):6678-88. PubMed ID: 21718050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.
    Megarity CF; Gill JR; Caraher MC; Stratford IJ; Nolan KA; Timson DJ
    FEBS Lett; 2014 May; 588(9):1666-72. PubMed ID: 24631540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
    Leung KK; Shilton BH
    Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based de novo design, molecular docking and molecular dynamics of primaquine analogues acting as quinone reductase II inhibitors.
    Murce E; Cuya-Guizado TR; Padilla-Chavarria HI; França TCC; Pimentel AS
    J Mol Graph Model; 2015 Nov; 62():235-244. PubMed ID: 26521207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acridones, new inhibitors of mitochondrial NADH: ubiquinone oxidoreductase (complex I).
    Oettmeier W; Masson K; Soll M
    Biochim Biophys Acta; 1992 Mar; 1099(3):262-6. PubMed ID: 1550833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).
    Michaelis S; Marais A; Schrey AK; Graebner OY; Schaudt C; Sefkow M; Kroll F; Dreger M; Glinski M; Koester H; Metternich R; Fischer JJ
    J Med Chem; 2012 Apr; 55(8):3934-44. PubMed ID: 22494098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective Properties of Quinone Reductase 2 Inhibitor M-11, a 2-Mercaptobenzimidazole Derivative.
    Voronin MV; Kadnikov IA; Zainullina LF; Logvinov IO; Verbovaya ER; Antipova TA; Vakhitova YV; Seredenin SB
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activity of ester derivatives of mycophenolic acid and acridines/acridones as potential immunosuppressive agents.
    Cholewinski G; Iwaszkiewicz-Grzes D; Trzonkowski P; Dzierzbicka K
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):974-82. PubMed ID: 26308114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting efflux pumps-In vitro investigations with acridone derivatives and identification of a lead molecule for MDR modulation.
    Singh P; Kaur J; Yadav B; Komath SS
    Bioorg Med Chem; 2010 Jun; 18(12):4212-23. PubMed ID: 20576574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
    Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
    Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Arylidene-2-oxindoles as Potent NRH:Quinone Oxidoreductase 2 Inhibitors.
    Lozinskaya NA; Bezsonova EN; Dubar M; Melekhina DD; Bazanov DR; Bunev AS; Grigor'eva OB; Klochkov VG; Sokolova EV; Babkov DA; Spasov AA; Sosonyuk SE
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.